Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2016-10-28

Clinical Trial Update: Bioequivalence of Two NovoLog® Formulations in Subjects With Type 1 Diabetes [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating the bioequivalence of two NovoLog insulin aspart formulations in adults with Type 1 diabetes has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • NovoLog (insulin aspart)

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Diabetes, Diabetes Mellitus, Type 1 | Phase 1 | Status: COMPLETED